138 related articles for article (PubMed ID: 23908504)
1. Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire.
Nixon J; McHugh C; Jones S
Clin Med (Lond); 2013 Aug; 13(4):358-61. PubMed ID: 23908504
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immune globulin usage for neurological and neuromuscular disorders: an academic centre, 4 years experience.
Sarti L; Falai T; Pinto F; Tendi E; Matà S
Neurol Sci; 2009 Jun; 30(3):213-8. PubMed ID: 19259617
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
4. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Patwa HS; Chaudhry V; Katzberg H; Rae-Grant AD; So YT
Neurology; 2012 Mar; 78(13):1009-15. PubMed ID: 22454268
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
[TBL] [Abstract][Full Text] [Related]
8. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
9. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders.
Grillo JA; Gorson KC; Ropper AH; Lewis J; Weinstein R
Neurology; 2001 Nov; 57(9):1699-701. PubMed ID: 11706114
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
[TBL] [Abstract][Full Text] [Related]
11. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
13. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis.
Moretti M; Buiatti A; Merlo M; Massa L; Fabris E; Pinamonti B; Sinagra G
Am J Cardiol; 2013 Nov; 112(9):1493-8. PubMed ID: 23972350
[TBL] [Abstract][Full Text] [Related]
15. Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders.
Menon D; Sarpong E; Bril V
Can J Neurol Sci; 2022 Mar; 49(2):161-167. PubMed ID: 33766159
[TBL] [Abstract][Full Text] [Related]
16. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
Waheed W; Ayer GA; Jadoo CL; Badger GJ; Aboukhatwa M; Brannagan TH; Tandan R
Muscle Nerve; 2019 Nov; 60(5):528-537. PubMed ID: 31443119
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency.
Ricci S; Lippi F; Canessa C; Guarnieri C; Macchia R; Azzari C
Int J Immunopathol Pharmacol; 2020; 34():2058738420943006. PubMed ID: 32924667
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Immunoglobulin Therapy in Refractory Autoimmune Dysautonomias: A Retrospective Analysis of 38 Patients.
Schofield JR; Chemali KR
Am J Ther; 2019; 26(5):570-582. PubMed ID: 29781817
[TBL] [Abstract][Full Text] [Related]
19. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
[TBL] [Abstract][Full Text] [Related]
20. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
